• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics (NQ: SRPT )

    125.01 +1.94 (+1.58%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sarepta Therapeutics

    < Previous 1 2 3 4 Next >
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
    Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
    Via MarketBeat
    Exposures Product Safety
    Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
    Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
    Via MarketBeat
    Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Stock Soars on FDA Approval
    Sarepta Therapeutics' expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market. 
    Via MarketBeat
    Exposures Product Safety
    Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Present at Upcoming Investor Conferences
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Gene therapy: Why does it cost millions for a single treatment?
    Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
    Via MarketBeat
    Exposures Product Safety
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.